Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy
Abstract Background The aim of this study was to investigate the efficacy of bevacizumab (Bev) in reducing peritumoral brain edema (PTBE) after stereotactic radiotherapy (SRT) for lung cancer brain metastases. Methods A retrospective analysis was conducted on 44 patients with lung cancer brain metas...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-11-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15106 |
| _version_ | 1827769620199636992 |
|---|---|
| author | Yi‐Chun Hua De‐Zhi Gao Kuan‐Yu Wang Xiao‐Sheng Ding Wei‐Ran Xu Yu‐Bin Li Wei‐Wei Shi Shi‐Bin Sun Xiao‐Yan Li |
| author_facet | Yi‐Chun Hua De‐Zhi Gao Kuan‐Yu Wang Xiao‐Sheng Ding Wei‐Ran Xu Yu‐Bin Li Wei‐Wei Shi Shi‐Bin Sun Xiao‐Yan Li |
| author_sort | Yi‐Chun Hua |
| collection | DOAJ |
| description | Abstract Background The aim of this study was to investigate the efficacy of bevacizumab (Bev) in reducing peritumoral brain edema (PTBE) after stereotactic radiotherapy (SRT) for lung cancer brain metastases. Methods A retrospective analysis was conducted on 44 patients with lung cancer brain metastases (70 lesions) who were admitted to our oncology and Gamma Knife center from January 2020 to May 2022. All patients received intracranial SRT and had PTBE. Based on treatment with Bev, patients were categorized as SRT + Bev and SRT groups. Follow‐up head magnetic resonance imaging was performed to calculate PTBE and tumor volume changes. The edema index (EI) was used to assess the severity of PTBE. Additionally, the extent of tumor reduction and intracranial progression‐free survival (PFS) were compared between the two groups. Results The SRT + Bev group showed a statistically significant difference in EI values before and after radiotherapy (p = 0.0115), with lower values observed after treatment, but there was no difference in the SRT group (p = 0.4008). There was a difference in the distribution of EI grades in the SRT + Bev group (p = 0.0186), with an increased proportion of patients at grades 1–2 after radiotherapy, while there was no difference in the SRT group (p > 0.9999). Both groups demonstrated a significant reduction in tumor volume after radiotherapy (p < 0.05), but there was no difference in tumor volume changes between the two groups (p = 0.4089). There was no difference in intracranial PFS between the two groups (p = 0.1541). Conclusion Bevacizumab significantly reduces the severity of PTBE after radiotherapy for lung cancer. However, its impact on tumor volume reduction and intracranial PFS does not reach statistical significance. |
| first_indexed | 2024-03-11T12:27:49Z |
| format | Article |
| id | doaj.art-c599f4596bad4261b9150979a8594d44 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-03-11T12:27:49Z |
| publishDate | 2023-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-c599f4596bad4261b9150979a8594d442023-11-06T07:15:22ZengWileyThoracic Cancer1759-77061759-77142023-11-0114313133313910.1111/1759-7714.15106Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapyYi‐Chun Hua0De‐Zhi Gao1Kuan‐Yu Wang2Xiao‐Sheng Ding3Wei‐Ran Xu4Yu‐Bin Li5Wei‐Wei Shi6Shi‐Bin Sun7Xiao‐Yan Li8Department of Oncology, Beijing Tiantan Hospital Capital Medical University Beijing ChinaDepartment of Gamma Knife center, Beijing Tiantan Hospital Capital Medical University Beijing ChinaDepartment of Gamma Knife center, Beijing Tiantan Hospital Capital Medical University Beijing ChinaDepartment of Oncology, Beijing Tiantan Hospital Capital Medical University Beijing ChinaDepartment of Oncology, Beijing Tiantan Hospital Capital Medical University Beijing ChinaDepartment of Oncology, Beijing Tiantan Hospital Capital Medical University Beijing ChinaDepartment of Oncology PLA General Hospital Beijing ChinaDepartment of Gamma Knife center, Beijing Tiantan Hospital Capital Medical University Beijing ChinaDepartment of Oncology, Beijing Tiantan Hospital Capital Medical University Beijing ChinaAbstract Background The aim of this study was to investigate the efficacy of bevacizumab (Bev) in reducing peritumoral brain edema (PTBE) after stereotactic radiotherapy (SRT) for lung cancer brain metastases. Methods A retrospective analysis was conducted on 44 patients with lung cancer brain metastases (70 lesions) who were admitted to our oncology and Gamma Knife center from January 2020 to May 2022. All patients received intracranial SRT and had PTBE. Based on treatment with Bev, patients were categorized as SRT + Bev and SRT groups. Follow‐up head magnetic resonance imaging was performed to calculate PTBE and tumor volume changes. The edema index (EI) was used to assess the severity of PTBE. Additionally, the extent of tumor reduction and intracranial progression‐free survival (PFS) were compared between the two groups. Results The SRT + Bev group showed a statistically significant difference in EI values before and after radiotherapy (p = 0.0115), with lower values observed after treatment, but there was no difference in the SRT group (p = 0.4008). There was a difference in the distribution of EI grades in the SRT + Bev group (p = 0.0186), with an increased proportion of patients at grades 1–2 after radiotherapy, while there was no difference in the SRT group (p > 0.9999). Both groups demonstrated a significant reduction in tumor volume after radiotherapy (p < 0.05), but there was no difference in tumor volume changes between the two groups (p = 0.4089). There was no difference in intracranial PFS between the two groups (p = 0.1541). Conclusion Bevacizumab significantly reduces the severity of PTBE after radiotherapy for lung cancer. However, its impact on tumor volume reduction and intracranial PFS does not reach statistical significance.https://doi.org/10.1111/1759-7714.15106bevacizumabbrain metastaseslung cancerperitumoral brain edemaradiotherapy |
| spellingShingle | Yi‐Chun Hua De‐Zhi Gao Kuan‐Yu Wang Xiao‐Sheng Ding Wei‐Ran Xu Yu‐Bin Li Wei‐Wei Shi Shi‐Bin Sun Xiao‐Yan Li Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy Thoracic Cancer bevacizumab brain metastases lung cancer peritumoral brain edema radiotherapy |
| title | Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy |
| title_full | Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy |
| title_fullStr | Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy |
| title_full_unstemmed | Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy |
| title_short | Bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy |
| title_sort | bevacizumab reduces peritumoral brain edema in lung cancer brain metastases after radiotherapy |
| topic | bevacizumab brain metastases lung cancer peritumoral brain edema radiotherapy |
| url | https://doi.org/10.1111/1759-7714.15106 |
| work_keys_str_mv | AT yichunhua bevacizumabreducesperitumoralbrainedemainlungcancerbrainmetastasesafterradiotherapy AT dezhigao bevacizumabreducesperitumoralbrainedemainlungcancerbrainmetastasesafterradiotherapy AT kuanyuwang bevacizumabreducesperitumoralbrainedemainlungcancerbrainmetastasesafterradiotherapy AT xiaoshengding bevacizumabreducesperitumoralbrainedemainlungcancerbrainmetastasesafterradiotherapy AT weiranxu bevacizumabreducesperitumoralbrainedemainlungcancerbrainmetastasesafterradiotherapy AT yubinli bevacizumabreducesperitumoralbrainedemainlungcancerbrainmetastasesafterradiotherapy AT weiweishi bevacizumabreducesperitumoralbrainedemainlungcancerbrainmetastasesafterradiotherapy AT shibinsun bevacizumabreducesperitumoralbrainedemainlungcancerbrainmetastasesafterradiotherapy AT xiaoyanli bevacizumabreducesperitumoralbrainedemainlungcancerbrainmetastasesafterradiotherapy |